1. Hisada T, Kondo N, Wanifuchi-Endo Y, Osaga S, Fujita T, Asano T, Uemoto Y, Nishikawa S, Katagiri Y, Terada M, Kato A, Sugiura H, Okuda K, Kato H, Komura M, Morita S, Takahashi S, Toyama T. Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer. Sci Rep. 2022 Oct 3;12(1):16515.
2. Kato A, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Uemoto Y, Terada M, Kato H, Komura M, Okuda K, Takahashi S, Toyama T. Low TINAGL1 expression is a marker for poor prognosis in breast cancer. J Cancer Res Clin Oncol. 2022 Oct 14. doi: 10.1007/s00432-022-04394-3. Online ahead of print
3. Terada M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Uemoto Y, Akiko Kato, Yamanaka N, Sugiura H, Mita K, Wada A, Takahashi E, Saito K, Yoshioka R, Toyama T. Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study. Breast Cancer Res Treat. 2022 Aug 8:1-13. doi: 10.1007/s10549-022-06693-2. Online ahead of print.
4. Terada M, Miyashita M, Kumamaru H, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Iijima K, Hayashi N, Kubo M, Yamamoto Y, Jinno H. Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry. Breast Cancer. 2022 Mar 22. doi: 10.1007/s12282-022-01348-y. Online ahead of print
5. Wanifuchi-Endo Y, Kondo N, Dong Y, Fujita T, Asano T, Hisada T, Uemoto Y, Nishikawa S, Katagiri Y, Kato A, Terada M, Sugiura H, Okuda K, Kato H, Takahashi S, Toyama T. Discovering novel mechanisms of taxane resistance in human breast cancer by whole-exome sequencing. Oncol Lett. 2022 Feb;23(2):60.
6. Habara M, Sato Y, Goshima T, Sakurai M, Imai H, Shimizu H, Katayama Y, Hanaki S, Masaki T, Morimoto M, Nishikawa S, Toyama T, Shimada M. FKBP52 and FKBP51 differentially regulate the stability of estrogen receptor in breast cancer. Proc Natl Acad Sci USA. 2022 Apr 12;119(15):e2110256119
7. Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2022 Apr 8:S1470-2045(22)00196-6. doi: 10.1016/S1470-2045(22)00196-6. Online ahead of print.
8. Uemoto Y, Katsuta E, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Terada M, Kato A, Okuda K, Sugiura H, Komura M, Kato H, Osaga S, Takahashi S, Toyama T. Low HECTD1 mRNA expression is associated with poor prognosis and may be correlated with increased mitochondrial respiratory function in breast cancer. Am J Cancer Res. 2022 Apr 15;12(4):1593-1605. eCollection 2022.
9. Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS). Cancer Sci. 2022 Jun 26. doi: 10.1111/cas.15474. Online ahead of print
10. Sawaki M, Taira N, Uemura Y, Saito S, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Toyama T, Tsugawa K, Kawaharat T, Mukai H, for the RESPECT study group. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study. The Breast. 2022 Dec;66:245-254. doi: 10.1016/j.breast.2022.10.017. Epub 2022 Nov 7.
11. Matsumoto N, Kondo N, Wanifuchi-Endo Y, Asano T, Hisada T, Uemoto Y, Kato A, Terada M, Yamanaka N, Isogai A, Takayama M, Hasegawa T, Ito K, Mashita K, Toyama T. Granulocyte colony-stimulating factor-associated aortitis in a woman with breast cancer: a case report. Surg Case Rep. 2022 Aug 18;8(1):157. doi: 10.1186/s40792-022-01514-6
12. Kikawa Y, MD, Hagiwara Y, Fujisawa T, Araki K, Iwamoto T, Sangai T, Shien T, Takao S, Nishimura R, Takahashi M, Toyama T, Aihara T, Mukai H, Taira N, Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom (FACT-ES) score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. PLOS ONE 2022 Nov 29;17(11):e0278344. doi: 10.1371/journal.pone.0278344. eCollection 2022.
13 Minohara K, Imai M, Matoba T, Wing JB, Shime H, Odanaka M, Uraki R, Kawakita D, Toyama T, Takahashi S, Morita A, Murakami S, Ohkura N, Sakaguchi S, Iwasaki S, Yamazaki S. Mature dendritic cells enriched in regulatory molecules may control regulatory T cells and the prognosis of head and neck cancer. Cancer Sci. 2022 Dec 18. doi: 10.1111/cas.15698. Online ahead of print.
2021
1. Nishikawa S, Uemoto Y, Kim TS, Hisada T, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Katagiri Y, Terada M, Kato A, Dong Y, Sugiura H, Okuda K, Kato H, Osaga S, Takahashi S, Toyama T. Low RAI2 expression is a marker of poor prognosis in breast cancer. Breast Cancer Res. Treat. 187(1):81–93, 2021
2. Nakatsukasa K, Niikura N, Kashiwabara K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Yamashita T, Umeda M, Mukai H, Ota Y. Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC treated with everolimus and exemestane enrolled in Oral Care-BC. BMC Cancer. 21(1):34, 2021.
3. Kurebayashi J, Shiba E, Toyama T, Matsumoto H, Okazaki M, Nomizu T, Ohtake T, Fujii T, Ohashi Y. A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer. 2021 May;28(3):684-697.
4. Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast Cancer. 28(1):145-160, 2021.
5. Akechi T, Momino K, Katsuki F, Yamashita H, Sugiura H, Yoshimoto N, Wanifuchi-Endo Y, Toyama T. Brief collaborative care intervention to reduce perceived unmet needs in highly distressed breast cancer patients: randomized controlled trial. Jpn J Clin Oncol. 51(2):244-251, 2021.
6. Sagara Y, Mori M, Yamamoto S, Eguchi K, Iwatani T, Naito Y, Kogawa T, Tanaka K, Kotani H, Yasojima H, Ozaki Y, Noguchi E, Miyasita M, Kondo N, Niikura N, Toi M, Shien T, Iwata H. Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer. Oncologist. 26(4):e686-e693, 2021.
7. Takashima T, Hara F, Iwamoto T, Uemura Y, Ohsumi S, Yotsumoto D, Hozumi Y, Watanabe T, Saito T, Watanabe KI, Tsurutani J, Toyama T, Akabane H, Nishimura R, Taira N, Ohashi Y, Mukai H. A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. Clin Breast Cancer. 2021 Oct;21(5):450-457.
8. Gondo N, Sakai Y, Zhang Z, Hato Y, Kuzushima K, Phimsen S, Kawashima Y, Kuroda M, Suzuki M, Okada S, Iwata H, Toyama T, Rezano A, Kuwahara K. Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas. Lab Invest. 2021 Aug;101(8):1048-1059.
9. Uemoto Y, Uchida M, Kondo N, Wanifuchi-Endo Y, Fujita T, Asano T, Hisada T, Nishikawa S, Katagiri Y, Terada M, Kato A, Okuda K, Sugiura H, Osaga S, Akechi T, Toyama T. Predictive factors for patients who need treatment for chronic post-surgical pain (CPSP) after breast cancer surgery. Breast Cancer 2021 Nov;28(6):1346-1357.
10. Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, Kuroi K, Morita S, Ohno S, Toi M, Masuda N. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Res Treat. 2021 Dec;190(3):425-434.
11. Umeda M, Ota Y, Kashiwabara K, Hayashi N, Naito M, Yamashita T, Mukai H, Nakatsukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Niikura N. Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC). Ann Transl Med. 2021 Apr;9(7):535.
2020
1. Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Shibuya Y, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y. Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. Oncologist. 2020 Feb;25(2):e223-e230.
2. Urano M, Denewar FA, Okabe H, Komatsu H, Wanifuchi-Endo Y, Toyama T, Shibamoto Y. Corrigendum to "Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings" [Radiology Case Reports 14 (2019) 584-587]. Radiol Case Rep. 2020 Sep 26;15(11):2494.
3. Hisoshima M, Urano M, Ohashi K, Ogawa M, Omata S, Yoshida S, Toyama T, Shibamoto Y. Utility of 70-kV single-energy CT in depicting the extent of breast cancer for preoperative planning. Breast Cancer Res Trea. 2020 Dec;184(3):817-823.
4. Kato H, Naiki-Ito A, Yamada T, Suzuki S, Yamashita Y, Inaguma S, Kondo N, Wanifuchi-Endo Y, Toyama T, Takahashi S. The standard form of CD44 as a marker for invasion of encapsulated papillary carcinoma of the breast. Pathol Int. 2020 Nov;70(11):835-843.
5. Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast Cancer. 2020 Jul 26. doi: 10.1007/s12282-020-01138-4. [Epub ahead of print]
6. Yap YS, Chiu J, Ito Y, Ishikawa T, Aruga T, Kim SJ, Toyama T, Saeki T, Saito M, Gounaris I, Su F, Ji Y, Han Y, Gazdoiu M, Masuda N. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer. Cancer Sci. 2020 Sep;111(9):3313-3326.
7. Yoshinami T, Koizumi K, Nagai SE, Toyama T, Iwata H. Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition. Breast Cancer. 2020 May;27(3):334-339.
8. Mukai H, Yamaguchi T, Takahashi M, Hozumi Y, Fujisawa T, Ohsumi S, Akabane H, Nishimura R, Takashima T, Park Y, Sagara Y, Toyama T, Imoto S, Mizuno T, Yamashita S, Fujii S, Uemura Y. Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. Br J Cancer. 2020 Jun;122(12):1747-1753.
9. Park YH, Senkus-Konefka E, Im SA, Pentheroudakis G, Saji S, Gupta S, Iwata H, Mastura MY, Dent R, Lu YS, Yin Y, Smruti BK, Toyama T, Malwinder S, Lee SC, Tseng LM, Kim JH, Kim TY, Suh KJ, Cardoso F, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.Ann Oncol. 2020 Apr;31(4):451-469.
10. Miyashita M, Hattori M, Takano T, Toyama T, Iwata H. Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer. 2020 May;27(3):347-354.
11. Iwata H, Saji S, Ikeda M, Inokuchi M, Uematsu T, Toyama T, Horii R, Yamauchi C. The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient. Breast Cancer. 2020 Jan;27(1):1-3.
12. Urano M, Nishikawa H, Goto T, Shiraki N, Matsuo M, Denewar FA, Kondo N, Toyama T, Shibamoto Y. Digital Mammographic Features of Breast Cancer Recurrences and Benign Lesions Mimicking Malignancy Following Breast-Conserving Surgery and Radiation Therapy. Kurume Med J. 2020 Jan 23;65(4):113-121.
13. Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, Kikawa Y, Koizumi K, Kondo N, Sagara Y, Takada M, Takano T, Tsurutani J, Naito Y, Nakamura R, Hattori M, Hara F, Hayashi N, Mizuno T, Miyashita M, Yamashita N, Yamanaka T, Saji S, Iwata H, Toyama T. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020 May;27(3):322-331.
14. Uemoto Y, Kondo N, Wanifuchi-Endo Y, Asano T, Hisada T, Nishikawa S, Katagiri Y, Terada M, Kato A, Okuda K, Sugiura H, Kato H, Takahashi S, Toyama T. Sentinel lymph node biopsy may be unnecessary for ductal carcinoma in situ of the breast that is small and diagnosed by preoperative biopsy. Jpn J Clin Oncol. 2020 Dec 16;50(12):1364-1369.
15. Shimoi T, Sagara Y, Hara F, Toyama T, Iwata H. First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis. Breast Cancer. 2020 May;27(3):340-346.
2019
1. Wanifuchi-Endo Y, Asano T, Kondo N, Hato Y, Dong Y, Hisada T, Nishikawa S, Kato H, Takahashi S, Okuda K, Yamashita H, Toyama T. Effects of serum estradiol and progesterone on estrogen-regulated gene expression in breast cancers of premenopausal patients. Jpn J Clin Oncol. 2019 Jan 1;49(1):12-21.
2. Kawaguchi M, Han X, Hisada T, Nishikawa S, Kano K, Ieda N, Aoki J, Toyama T, Nakagawa H. Development of an ENPP1 Fluorescence Probe for Inhibitor Screening, Cellular Imaging, and Prognostic Assessment of Malignant Breast Cancer. J Med Chem 2019 Oct 24;62(20):9254-9269.
3. Matoba T, Imai M, Ohkura N, Kawakita D, Ijichi K, Toyama T, Morita A, Murakami S, Sakaguchi S, Yamazaki S. Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer. Int J Cancer. 2019 Jan 1;49(1):12-21.
4. Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat 2019 Jan;173(1):123-133.
5. Nishimoto M, Nishikawa S, Kondo N, Wanifuchi-Endo Y, Hato Y, Hisada T, Dong Y, Okuda K, Sugiura H, Kato H, Takahashi S, Toyama T. Prognostic impact of TP53INP1 gene expression in estrogen receptor α-positive breast cancer patients. Jpn J Clin Oncol. 2019 Jun 1;49(6):567-575.
6. Imai F, Momino K, Katsuki F, Horikoshi M, Furukawa TA, Kondo N, Toyama T, Yamaguchi T, Akechi T. Smartphone problem-solving therapy to reduce fear of cancer recurrence among breast cancer survivors: an open single-arm pilot study. Jpn J Clin Oncol. 2019 Jan;173(1):123-133.
7. Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Wanifuchi-Endo Y, Hosoda M, Doihara H, Yamashita H.Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. Oncol Lett. 2019 Feb;17(2):2177-2186.
8. Urano M, Denewar FA, Okabe R, Komatsu H, Wanifuchi-Endo Y, Toyama T, Shibamoto Y. Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings. Radiol Case Rep. 2019 Mar 5;14(5):584-587.
2018
1. Loh JT, Lim TJF, Ikumi K, Matoba T, Janela B, Gunawan M, Toyama T, Bunjamin M, Ng LG, Poidinger M, Morita A, Ginhoux F, Yamazaki S, Lam KP, Su IH. Ezh2 Controls Skin Tolerance through Distinct Mechanisms in Different Subsets of Skin Dendritic Cells. iScience 21;10:23-39, 2018.
2. Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, Masuda N, Morita S, Toi M, Ohno S. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. Jpn J Clin Oncol. 48(9):855-859, 2018.
3. Toyama T, Yoshimura A, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, Sawaki M, Hattori M, Nakada T, Yokota I, Iwata H. A randomized phase II study evaluating pyridoxine for the prevention of hand–foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. Breast Cancer 25(6):729-735, 2018.
4. Royce M, Bachelot T, Villanueva C, Özgüroglu M, Azevedo SJ, Cruz FM, Debled M, Hegg R, Toyama T, Falkson C, Jeong J, Srimuninnimit V, Gradishar WJ, Arce C, Ridolfi A, Lin C, Cardoso F. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. JAMA Oncol. 4(7):977-984, 2018.
5. Shimoi T, Shimomura A, Shien T, Uemura Y, Kato H, Kitada M, Toyama T, Aihara T, Mukai H. Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial). Open Access Journal of Clinical Trials. 2018:10 13–18
2017
1. Guo J, Sueta A, Nakamura K, Yoshimoto N, Baba M, Ishida N, Hagio K, Toyama T, Iwase H, Tamakoshi A, Yamashita H, Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women. Oncotarget. 8(39):65759-65769, 2017.
2. Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y. A randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Cancer Sci. 108(5):987-994, 2017.
3. Ito Y, Inoue A, Seers T, Hato Y, Igarashi A, Toyama T, Taganov KD, Boldin MP, Asahara H. Identification of targets of tumor suppressor microRNA-34a using a reporter library system. Proc Natl Acad Sci U S A. 114(15):3927-3932, 2017.
4. Kurebayashi J, Toyama T, Sumino S, Miyajima E, Fujimoto T. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study. Breast Cancer. 24:161–170, 2017.
5. Momino K, Mitsunori M, Yamashita H, Toyama T, Sugiura H, Yoshimoto N, Hirai K, Akechi T. Collaborative care intervention for the perceived care needs of women with breast cancer undergoing adjuvant therapy after surgery: a feasibility study. Jpn J Clin Oncol. 47(3):213-220, 2017.
6. Ogiya A, Yamazaki K, Horii R, Shien T, Horimoto Y, Masuda N, Inao T, Hosoda M, Ishida N, Osako T, Takahashi M, Endo Y, Miyoshi Y, Yasojima H, Tomioka N, Yamashita H; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer. 24(3):473-482, 2017.
7. Adachi Y, Yoshimura M, Nishida K, Usuki H, Shibata K, Hattori M, Kondo N, Yatabe Y, Iwata H, Kikumori T, Kodera Y, Nakanishi H. Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models. Breast Cancer Res Treat. 167(2):439-450, 2017.
2016
Endo Y, Dong Y, Kondo N, Yoshimoto N, Asano T, Hato Y, Nishimoto M, Kato H, Takahashi S, Nakanishi R, Toyama T. HER2 mutation status in Japanese HER2-positive breast cancer patients. Breast Cancer. 23(6):902-907, 2016.
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC study group. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 17(1):90-8, 2016.
Hato Y, Kondo N, Yoshimoto N, Endo Y, Asano T, Dong Y, Nishimoto M, Takahashi S, Fujii Y, Nakanishi R, Toyama T. Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients. Int J Clin Oncol. 2015 Oct 19. 21(3):539-47, 2016.
Takayama T, Tsutsui H, Shimizu I, Toyama T, Yoshimoto N, Endo Y, Inoue K, Todoroki K, Min JZ, Mizuno H, Toyo'oka T. Diagnostic approach to breast cancer patients based on target metabolomics in saliva by liquid chromatography with tandem mass spectrometry. Clin Chim Acta. 452:18-26, 2016.
Urano M, Shiraki N, Kawai T, Goto T, Endo Y, Yoshimoto N, Toyama T, Shibamoto Y. Digital mammography versus digital breast tomosynthesis for detection of breast cancer in the intraoperative specimen during breast-conserving surgery. Breast Cancer. 23(5):706-11, 2016.
Urano M, Shiraki N, Hara M, Toyama T, Shibamoto Y. Multi-detector row CT-guided marking technique for breast-conserving therapy of early breast cancer: margin positivity and local control rates. Breast Cancer. 23(2):252-60, 2016.
Yamashita H, Ogiya A, Shien T, Horimoto Y, Masuda N, Inao T, Osako T, Takahashi M, Endo Y, Hosoda M, Ishida N, Horii R, Yamazaki K, Miyoshi Y, Yasojima H, Tomioka N. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 23(6):830-843, 2016.
Miyoshi Y, Shien T, Ogiya A, Ishida N, Yamazaki K, Horii R, Horimoto Y, Masuda N, Yasojima H, Inao T, Osako T, Takahashi M, Tomioka N, Endo Y, Hosoda M, Doihara H, Miyoshi S, Yamashita H. Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. Breast Cancer Res. 18(1):73. 2016.
Hisada T, Sawaki M, Ishiguro J, Adachi Y, Kotani1 H, Yoshimura A, Hattori M, Yatabe Y, Iwata H. Impact of intraoperative specimen mammography on margins in breast-conserving surgery. Mol Clin Oncol. 5: 269-272, 2016.
2015
Akechi T, Momino K, Miyashita M, Sakamoto N, Yamashita H, Toyama T. Anxiety in disease free breast cancer patients might be alleviated by provision of psychological support, not of information. Jpn J Clin Oncol. 2015 Jul 16. [Epub ahead of print]
Akechi T, Uchida M, Nakaguchi T, Okuyama T, Sakamoto N, Toyama T, Yamashita H. Difference of patient's perceived need in breast cancer patients after diagnosis. Jpn J Clin Oncol. 45(1):75-80. 2015.
Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S. The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer. Breast Cancer. 22(1):5-15, 2015.
Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. 22(3):308-16, 2015
Akechi T, Momino K, Miyashita M, Sakamoto N, Yamashita H, Toyama T. Anxiety in disease free breast cancer patients might be alleviated by provision of psychological support, not of information. Jpn J Clin Oncol. 45(10):929-33, 2015.
Akechi T, Uchida M, Nakaguchi T, Okuyama T, Sakamoto N, Toyama T, Yamashita H. Difference of patient's perceived need in breast cancer patients after diagnosis. Jpn J Clin Oncol. 45(1):75-80. 2015.
Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S. The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer. Breast Cancer. 22(1):5-15, 2015.
Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. 22(3):308-16, 2015
2014
Endo Y, Yamashita H, Takahashi S, Sato S, Yoshimoto N, Asano T, Hato Y, Dong Y, Fujii Y, Toyama T. Immunohistochemical determination of arylamine N-acetyltransferase 1 (NAT1) as the target of miR-1290 and prognostic biomarker of breast cancer. BMC Cancer.14(1):990, 2014.
Urano M, Shiraki N, Hara M, Toyama T, Shibamoto Y. Multi-detector row CT-guided marking technique for breast-conserving therapy of early breast cancer: margin positivity and local control rates. Breast Cancer. 2014 Sep 3. [Epub ahead of print]
Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M. Gustafsson JA. Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer. Proc Natl Acad Sci USA. 111(5):1933-8, 2014.
Kawakubo T, Yasukochi A, Toyama T, Takahashi S, Okamoto K, Tsukuba T, Nakamura S, Ozaki Y, Nishigaki K, Yamashita H, Yamamoto K. Repression of cathepsin E expression increases the risk of mammary carcinogenesis and links to poor prognosis in breast cancer.Carcinogenesis. 35(3):714–726, 2014.
Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K, Sahashi T, Kuroda J, Ogura H, Uegaki S, Yoshida T, Mori Y, Sawada H, Watanabe S, Sugiura H, Endo Y, Yoshimoto N, Toyama T, Iida S, Yamada K, Kimura K, Wakita A. Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients. Journal of Cancer. 5(5):390-397, 2014.
Endo Y, Dong Y, Yoshimoto N, Asano T, Hato Y, Yamashita H, Sato S, Takahashi S, Fujii Y, Toyama T. HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients. Jpn J Clin Oncol. 44(7):619-23. 2014.
Asano T, Sato S, Yoshimoto N, Endo Y, Hato Y, Dong Yu, Takahashi S, Fujii Y, Toyama T. High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients. Jpn J Clin Oncol. 44(10):889-97, 2014.
2013
Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H. MiR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. Endocr Relat Cancer. 20(1):91-102, 2013.
Endo Y, Sugiura H, Yamashita H,Takahashi S,Yoshimoto N, Iwasa M, Asano, Toyama T. Myoepithelial Carcinoma of the Breast Treated with Surgery and Chemotherapy. Case Rep Oncol Med. 164761, 2013.
Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Iwata H, Yamashita H, Toyama T, Chishima T, Saji S, Yamamoto-Ibusuki M, Iwase H. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. BMC Cancer. 13(1):239, 2013.
Tsutsui H, Mochizuki T, Inoue K, Toyama T, Yoshimoto N, Endo Y, Todoroki K, Min JZ, Toyo'oka T. High-Throughput LC-MS/MS Based Simultaneous Determination of Polyamines Including N-Acetylated Forms in Human Saliva and the Diagnostic Approach to Breast Cancer Patients. Anal Chem. 85(24):11835-42, 2013.
Snyder CF, Blackford AL, Okuyama T, Akechi T, Yamashita H, Toyama T, Carducci MA, Wu AW. Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention. Qual Life Res. 22(10):2685-91, 2013.
2012
Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, Takahashi S, Fujii Y, Yamashita H. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol. 42(4):256-63, 2012.
Kobayashi S, Sugiura H, Ando Y, Shiraki N, Yanagi T, Yamashita H, Toyama T. Reproductive history and breast cancer risk. Breast Cancer. 19(4):302-8, 2012.
Akechi T, Okuyama T, Uchida M, Nakaguchi T, Ito Y, Yamashita H, Toyama T, Komatsu H, Kizawa Y, Wada M. Perceived needs, psychological distress and quality of life of elderly cancer patients. Jpn J Clin Oncol. 42(8):704-10, 2012.
2011
Okuyama T, Akechi T, Yamashita H, Toyama T, Nakaguchi T, Uchida M, Furukawa TA. Oncologists' recognition of supportive care needs and symptoms of their patients in a breast cancer outpatient consultation. Jpn J Clin Oncol. 41(11):1251-8, 2011.
Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res Treat. 130(1):331-9, 2011
Yoshimoto N, Nishiyama T, Toyama T, Takahashi S, Shiraki N, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H. Genetic and environmental predictors, endogenous hormones and growth factors and risk of estrogen receptor-positive breast cancer in Japanese women.Cancer Sci. 102(11):2065-72, 2011.
Endo Y, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Iwasa M, Kobayashi S, Fujii Y, Yamashita H. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol. 16(5):512-8, 2011.
Yamashita H, Toyama T, Sugiura H, Yoshimoto N, Endo Y, Iwasa M, Fujii Y, Kobayashi S. Management of recurrent breast cancer without systemic therapy but with natural menopause as endocrine therapy: a report of two cases. The Open Breast Cancer Journal 3:10-12, 2011.
Uchida M, Akechi T, Okuyama T, Sagawa R, Nakaguchi T, Endo C, Yamashita H, Toyama T, Furukawa TA. Patients' supportive care needs and psychological distress in advanced breast cancer patients in Japan. Jpn J Clin Oncol. 41(4):530-6, 2011.
Akechi T, Okuyama T, Endo C, Sagawa R, Uchida M, Nakaguchi T, Akazawa T, Yamashita H, Toyama T, Furukawa TA. Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. Psychooncology. 20(5):497-505, 2011.
Uchida M, Akechi T, Okuyama T, Sagawa R, Nakaguchi T, Endo C, Yamashita H, Toyama T, Furukawa TA. Patients' Supportive Care Needs and Psychological Distress in Advanced Breast Cancer Patients in Japan. Jpn J Clin Oncol. 41(4):530-6, 2011.
Yamashita H, Iwase H, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Endo Y, Fujii Y, Kobayashi S. Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. Ann Oncol 22(6):1318-25, 2011.
2010
Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.Breast Cancer. 17(4):298-302, 2010.
Sawaki M, Iwata H, Sato Y, Wada M, Toyama T, Sasaki E, Yatabe Y, Imai T, Ohashi Y. Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. Breast. 19(5):370-6, 2010.
2009
Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment. Jpn J Clin Oncol. 39(10):651-6, 2009.
Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.Breast Cancer. 17(4):298-302, 2009.
Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor–positive breast cancer, Cancer Sci. 100(11):2028-33, 2009.
Zhang ZH, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Ibusuki M, Tomita S, Sugiura H, Kobayashi S, Fujii Y, Iwase H. Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse.Chin Med J 122(15):1764-1768. 2009.
Okuyama T, Akechi T, Yamashita H, Toyama T, Endo C, Sagawa R, Uchida M, Furukawa TA. Reliability and validity of the Japanese version of the Short-form Supportive Care Needs Survey Questionnaire (SCNS-SF34-J). Psychooncology 18(9):1003-10, 2009.
2008
Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H: miR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res 68: 5004-5008, 2008
Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H: Low phosphorylation of ERα serine 118 and high phosphorylation of ERα serine 167 improve survival in ER-positive breast cancer. Endocr-Relat Cancer 15: 755-763, 2008
Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y:Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 8: 309, 2008
Hamaguchi M, Nishio M, Toyama T, Sugiura H, Kondo N, Fujii Y, Yamashita H: Possible difference in frequencies of genetic polymorphisms of estrogen receptor α, estrogen metabolism and p53 genes between estrogen receptor-positive and -negative breast cancers. Jpn J Clin Oncol 38: 734-742, 2008
Kai K, Zhang Z, Yamashita H, Yamamoto Y, Miura Y, Iwase H: Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer. BMC Cancer 8: 262, 2008
Okumura Y, Yamamoto Y, Zhang Z, Toyama T, Kawasoe T, Ibusuki M, Honda Y, Iyama K, Yamashita H, Iwase H: Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. BMC Cancer 8: 287, 2008
Yamashita H: Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol 13: 380-383, 2008 (review)
Kobayashi S: Basal-like subtype of breast cancer: a review of its unique characteristics and clinical significance. Breast Cancer 15: 153-158, 2008 (review)
2007
Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y: Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9: R34, 2007
Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H: Expression of estrogen receptor β wild-type and its variant ERβcx/β2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 37: 820-828, 2007
Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, Hayashi S, Fujii Y, Iwase H, Yamashita H: Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol 37: 575-582, 2007
Naiki-Ito A, Asamoto M, Hokaiwado N, Takahashi S, Yamashita H, Tsuda H, Ogawa K, Shirai T: Gpx2 is an overexpressed gene in rat breast cancers induced by three different chemical carcinogens. Cancer Res 67: 11353-11358, 2007
Arihiro K, Umemura S, Kurosumi M, Moriya T, Oyama T, Yamashita H, Umekita Y, Komoike Y, Shimizu C, Fukushima H, Kajiwara H, Akiyama F: Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays. Am J Clin Pathol 127: 356-365, 2007
Fujinaka Y, Takane K, Yamashita H, Vasavada RC: Lactogens promote beta cell survival through JAK2/STAT5 activation and BCL-XL upregulation. J Biol Chem 282: 30707-30717, 2007
2006
Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, and Iwase H: Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res 12: 6410-6414, 2006
Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H: Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr-Relat Cancer 13: 885-893, 2006
Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H: p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8: R48, 2006
Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H: NCOR1 mRNA is an independent prognostic factor for breast cancer.Cancer Lett 237: 123-129, 2006
Toyama T, Zhang Z, Iwase H, Yamashita H, Ando Y, Hamaguchi M, Mizutani M, Kondo N, Fujita T, Fujii Y, Iwata H: Low expression of the Snail gene is a good prognostic factor in node-negative invasive ductal carcinomas. Jpn J Clin Oncol 36: 357-363, 2006
Yamashita H, Ando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H: Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13: 74-83, 2006
Umemura S, Kurosumi M, Moriya T, Oyama T, Arihiro K, Yamashita H, Umekita Y, Komoike Y, Shimizu C, Fukushima H, Kajiwara H, Akiyama F: Immunohistochemical evaluation for hormone receptors in breast cancer: A practically useful evaluation system and handling protocol. Breast Cancer 13: 232-235, 2006
Yamashita T, Yamashita H, Itoh Y, Karamatsu S, Itoh K, Hara Y, Ando Y, Sugiura H, Kuzushima T, Toyama T, Iwata H, Kobayashi S, Iwase H: Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5-DFUR) and cyclophosphamide for metastatic breast cancer. Breast Cancer 13: 334-339, 2006
2005
Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Kawaguchi M, Miura Y, Iwase H: ATBF1-A messenger RNA expression is correlated with better prognosis in breast cancer. Clin Cancer Res 11: 193-198, 2005
Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H: Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 7: R753-R764, 2005
Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H: Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast cancer Res Treat 94: 11-16, 2005
2004
Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S-I, Iwase H: HDAC6 expression is correlated with better prognosis in breast cancer.Clin Cancer Res 10: 6962-6968, 2004
Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H:
Coexistence of HER2 overexpression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6: R24-R30, 2004
Yamashita H, Nishio M, Fujii Y, Iwase H: Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. Cancer Sci 95: 662-665, 2004
Nishimura R, Tominaga T, Mitsuyama S, Aoyama H, Asaga T, Ohno S, Okuyama N, Kimura M, Iwase H, Kanda K, Koga T, Shiba E, Ikeda T: Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval. Anticancer Res 24: 2085-91, 2004
Toyama T, Iwase H: p33ING1b and estrogen receptor (ER) alpha. Breast Cancer 11: 33-37, 2004 (review)
Kobayashi S: What caused the decline in breast cancer mortality in the United Kingdom?Breast Cancer 11: 156-159, 2004 (review)
2003
Yamashita H, Iwase H, Toyama T, Fujii Y:
Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells.
Oncogene 22: 1638-1652, 2003
Toyama T, Iwase H, Yamashita H, Hara Y, Sugiura H, Zhang Z, Fukai I, Miura Y, Riabowol K, Fujii Y:
p33ING1b stimulates the transcriptional activity of the estrogen receptor α via its activation function (AF) 2 domain.
J Steroid Biochem Mol Biol 87: 57-63, 2003
Iwase H, Omoto Y, Toyama T, Yamashita Y, Hara Y, Sugiura H, Zhang Z:
Clinical significance of AIB1 expression in breast cancer.
Breast Cancer Res Treat 80: 339-345, 2003
Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Wu X, Kobayashi S, Iwase H:
Quantitative determination by real-time RT-PCR of aromatase mRNA in invasive ductal carcinoma of the breast.
Breast Cancer Res 5: R250-R256, 2003
Toyama T, Iwase H, Yamashita H, Hara Y, Omoto Y, Sugiura H, Zhang Z, Fujii Y:
Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer.
Cancer Lett 189: 97-102, 2003
Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Haruki N, Kobayashi S, Iwase H:
Estrogen receptor alpha mutation (A-to-G transition at mucleotide 908) is not found in different types of breast lesions from Japanese women.
Breast Cancer 10: 70-73, 2003
Toyama T, Yamashita H, Hara Y, Sugiura H, Fujii Y, Iwase H:
Biweekly paclitaxel in patients with metastatic breast cancer.
Int J Clin Oncol 8: 357-361, 2003
Iwase H, Zhang Z, Omoto Y, Sugiura H, Yamashita H, Toyama T, Iwata H, Kobayashi S:
Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
Cancer Chemother Pharmacol 52: 34-38, 2003 (review)
Iwase H:
Molecular action of the estrogen receptor and hormone dependency in breast cancer.
Breast Cancer 10: 89-96, 2003 (review)
2002
Zhang Z, Yamashita H, Toyama T, Omoto Y, Hara Y, Sugiura H, Kobayashi S, Harada N, Iwase H:
Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
Breast Cancer Res Treat 74: 47-53, 2002
Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson JA, Iwase H:
Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers.
Eur J Cancer 38: 380-386, 2002
Yamashita H, Iwase H:
The role of Stat5 in estrogen receptor-positive breast cancer.
Breast Cancer 9: 312-318, 2002 (review)
Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, Riabowol K:
ING1 isoforms differentially affect apoptosis in a cell age-dependent manner.
Cancer Res 62: 4445-4452, 2002
Moriyama S, Nakashima Y, Yano M, Kaji M, Yamakawa Y, Toyama T, Yamashita H, Iwase H, Sasaki H, Saito Y, Kiriyama M, Kato J, Fujii Y:
Ratio of expression of p16(INK4a) to p14(ARF) correlates with the progression of non-small cell lung cancer.
Jpn J Cancer Res 93: 783-788, 2002
Mitsui A, Kuwabara Y, Iwase H, Mitani M, Shinoda N, Sato A, Toyama T, Sugiura M, Suzuki T, Kato J, Fujii Y:
Telomerase activity in esophageal squamous cell carcinoma: Down-regulation by chemotherapeutic agent.
J Surg Oncol 79: 37-45, 2002
2001
Iwase H, Ando Y, Ichihara S, Toyoshima S, Nakamura T, Karamatsu S, Ito Y, Toyama T, Yamashita Y, Omoto Y, Mitsuyama S, Kobayashi S:
Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
Breast Cancer 8: 98-104, 2001
Iwata H, Yamamoto M, Nemori R, Mizutani M, Iwase T, Miura S, Obata Y, Hara Y, Omoto Y, Toyama T, Yamashita H, Iwase H, Kobayashi S:
Localization of gelatinolytic activity can be detected in breast cancer tissues by film in situ zymography.
Breast Cancer 8: 111-5, 2001
Omoto Y, Inoue S, Iwase H, Yamashita H, Toyama T, Hara Y, Ogawa S, Muramatsu M, Kobayashi S:
Clinical value of the wild-type estrogen receptor beta expression in breast cancer.
Cancer Lett 163: 207-212, 2001
Hara Y, Iwase H, Toyama T, Yamashita H, Omoto Y, Fujii Y, Kobayashi S:
Telomerase activity levels are useful in evaluating the surgical margin in breast conserving surgery for breast cancer.
Surg Today 31: 289-94, 2001
Naito A, Iwase H, Kuzushima T, Nakamura T, Kobayashi S:
Clinical significance of E-cadherin expression in thyroid neoplasms.
J Surg Oncol 76: 176-80, 2001
Toyama T, Yamashita H, Hara Y, Hikosaka Y, Kobayashi S, Iwase H:
Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment.
Int J Clin Oncol 6: 306-309, 2001
Ito Y, Iwase H, Tanaka H, Yuasa H, Kureyama Y, Yamashita H, Toyama T, Kimura M, Kobayashi S:
Metachronous primary hyperparathyroidism due to a parathyroid adenoma and a subsequent carcinoma report of a case.
Surgery Today 31: 895-898, 2001
Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, IshikawaY, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson Jk, Hayashi S-I:
Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers.
Biochem Biophys Res Commun 285: 340-347, 2001
Park S-H, Yamashita H, Rui H, Waxman DJ:
Serine phosphorylation of growth hormone-activated STAT5a and STAT5b: Impact on STAT5 transcriptional activity.
Mol Endocrinol 15: 2157-2171, 2001
2000
Ando Y, Iwase H, Ichihara S, Toyoshima S, Nakamura T, Yamashita H, Toyama T, Omoto Y, Karamatsu S, Mitsuyama S, Fujii Y, Kobayashi S:
Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast.
Cancer Lett 156: 207-214, 2000
Itoh Y, Tanaka H, Iwase H, Karamatsu S, Yamashita H, Itoh K, Yamashita T, Toyama T, Omoto Y, Kobayahsi S:
Readministration of tamoxifen after adjuvant therapy for recurrent breast cancer.
Breast Cancer 7: 149-152, 2000
Kobayashi S, Ito Y, Ando Y, Omoto Y, Toyama T, Iwase H:
Comparison of Five Different antibodies in the immunohistochemical assay of estrogen receptor alpha in human breast cancer.
Breast Cancer 7: 136-141, 2000
Omoto Y, Iwase H, Iwata H, Hara Y, Ando Y, Kobayashi S:
Expression of estrogen receptor alpha exon 5 and 7 deletion variant in human breast cancer.
Breast Cancer 7: 27-31, 2000
Moriya T, Kasami M, Akiyama F, Ichihara S, Kurosumi M, Tsuda H, Umemura S, Akashi-Tanaka S, Imamura H, Iwase H, Shin E, Harada Y, Mitsuyama S, Ohuchi N:
A proposal for histopathological diagnosis of ductal carcinoma in situ of the breast.
Breast Cancer 7: 321-325, 2000
Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S and Fujii Y:
Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography.
Eur J Cancer 36: 2164-2170, 2000
Nomura Y, Masaoka A, Fujii Y, Kobayashi S, Iwase H, Iwata H. et al:
Clinical dosage determination of a new aromatase inhibitor, anastrozole, in postmenopausal Japanese women with advanced breast cancer.
Clin Drug Invest 20: 357-369, 2000
Kurebayashi J, Sonoo H, Inaji H, Nishimura R, Iino Y, Toi M, Kobayashi S, Saeki T:
Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies.
Oncology 59 (suppl 1): 31-37, 2000
Iwase H, Iwata H, Omoto Y, Toyama T, Hara Y, Ando Y, Ito Y, Fujii Y, Kobayashi S:
DNA methylation analysis at diatal and proximal promotor regions of the oestrogen receptor gene in breast cancers.
Br J Cancer 80: 1982-1986, 1999
Iwase H, Omoto Y, Toyama T, Hara Y, Kobayahsi S:
Clinical significance of estrogen receptor beta in breast cancer.
Breast Cancer 6: 325-330, 1999
Kobayashi S, Iwase H, Kuzushima K, Iwata H, Toyama T, Hara Y, Omoto Y, Ando Y, and Nakamura T:
Consecutively occuring multiple fibroadenomas of the breast distingushed from phyllodes tumors by clonality analysis of stromal tissues.
Breast Cancer 6: 201-206, 1999
Omoto Y, Iwase H, Iwata H, Hara Y, Ando Y, Kobayashi S:
Upper airway obstruction due to benign goiter: Report of three cases.
Thyroidol Clin Exp 11: 57-59, 1999
Toyama T, Iwase H, Garkavtsev I, Watson P, Muzik H, Saettler E, Magliocco A, DiFrancesco L, Forsyth P, Kobayashi S, Riabowol K:
Suppression of ING1 expression in sporadic breast cancer.
Oncogene 18: 5187-5193, 1999
Yamashita H, Xu J, Erwin RA, Larner AC, Rui H:
A lymphoma growth inhibitior blocks some but not all prolactin-stimulated signaling pathways.
J Biol Chem 274: 14699-14705, 1999
Ohmori M, Nagai M, Tasaka T, Koeffler HP, Toyama T, Riabowol K, Takahara J:
Decreased expression of p33ING1 mRNA in lymphoid malignancies.
Am J Hematol 62: 118-9, 1999
1998
Kobayashi S, Iwase H, Kawarada Y, Miura N, Sugiyama T, Iwata H, Hara Y, Omoto Y, Nakamura T:
Detection of DNA fragmentation in human breast cancer tissue by an antibody specific to single-stranded DNA.
Breast Cancer 5: 47-52, 1998
Iwase H, Omoto Y, Iwata H, Hara Y, Ando Y, Kobayashi S:
Genetic and epigenetic alteration of the estrogen receptor gene and hormone independence in human breast cancer.
Oncology 55 (Suppl 1):11-6, 1998 (review)
Kobayashi S, Tajima T:
Current insights in the mechanisms of carcinogenesis, progress, and metastasis of breast cancer.
Breast Cancer 5: 340-343, 1998 (review)
Kobayashi S, Fujimori M, Shingu K, Ito K, Hama K, Amano J:
Clinical micro carcinoma of the thyroid gland.
Thyroid Clin Exp 10: 175-176, 1998
Kobayashi S, Iwase H, Toyama T, Hara Y, Omoto Y, Nakamura T:
Absence of microsatellite instability in thyroid tumors from Japanese patients.
Thyroid Clin Exp 10: 1-6, 1998
Wanibe M, Mizuno H, Watanabe M, Matsuba K, Iwase H, Kobayashi S:
Effectiveness of thyroid hormone rectal suppositories in thyroidectomized patients.
J Applied Therapeutic Res 2: 133-140, 1998
Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H:
Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells.
J Biol Chem 273: 30218-30224, 1998
Parr E, Toyama T, Hull C, Meyyappan M, Bestilny L, Wheaton K, Riabowol K:
Molecular aspects of cellular senescence in human diploid fibloblasts.
Current Science, 74: 878-883, 1998
1997
Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, Ito K, Toyama T, Nakamura T, Masaoka A:
Clinical significance of bcl-2 gene expression in human breast cancer tissues.
Breast Cancer Res Treat 42: 173-181, 1997
Iwase H, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Toyama T, Hara Y, Masaoka A:
Simultaneous quantitative analysis of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
Cancer Detect Prevent 21: 29-35, 1997
Iwase H, Iwata H, Toyama T, Hara Y, Omoto Y, Ando Y, Nakamura T, Kobayashi S:
The clinical value of microsatellite instability and a loss in heterozygosity in sporadic breast cancers.
Breast Cancer 4: 234-238, 1997
Iwase H, Kobayashi S:
Alterations and polymorphisms of the estrogen receptor gene in breast cancer.
Breast Cancer 4: 57-66, 1997 (review)
1996
Toyama T, Iwase H, Yamashita H, Yamashita T, Ito K, Hara Y, Suchi M, Kato T, Nakamura T, Kobayashi S:
Microsatellite instability in sporadic human breast cancer.
Int J Cancer 68: 447-451, 1996
Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y:
Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas.
Jpn J Cancer Res 87: 602-611, 1996
Iwase H, Greenman JM, Barnes DM, Hodgson S, Bobrow L, Mathew CG:
Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors.
Cancer Lett 108: 179-184, 1996
Toyama T, Iwase H, Iwata H, Hara Y, Omoto Y, Suchi M, Kato T, Nakamura T, Kobayashi S:
Microsatellite instability in in situ and invasive breast cancer of Japanese women.
Cancer Lett 108: 205-209, 1996
Yamashita T, Iwase H, Yamashita H, Iwata H, Ito K, Toyama T, Hara Y, Kobayashi S:
Low frequent loss of heterozygosity in the BRCA 1 region in Japanese sporadic breast cancer.
Breast Cancer 3: 167-172, 1996
Iwata H, Kobayashi S, Iwase H, Itoh Y, Kuzushima T, Naitoh A, Yamashita T, Itoh K, Toyama T, Masaoka A:
Flow cytometric assay of c-erbB-2 protein in fine needle aspirates of fresh and frozen human breast cancer tissues.
Breast Cancer 3: 111-117, 1996
1995
Iwase H, Greenman JM, Baenes DM, Bobrow L, Hodgson S, Mathew CG:
Loss of heterozygosity of the oestrogen receptor gene in breast cancer.
Br J Cancer 71: 448-450, 1995
Itoh Y, Kobayashi S, Iwase H, Yamashita H, Kuzushima T, Iwata H, Yamashita T, Naito A, Itoh K, Masaoka A:
Clinical significance of cathepsin D assay in breast cancer tissues.
J Surg Oncol 60: 221-226, 1995
1994
Iwase H, Kobayashi S, Itoh Y, Fukuoka H, Kuzushima T, Iwata H, Yamashita T, Naitoh A, Itoh K, Masaoka A:
Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer.
Breast Cancer Res Treat 33: 83-88, 1994
Yamashita H, Kobayashi S, Iwase H, Itoh Y, Masaoka A:
Recurrent breast cancer at 21 years after resection detected by serum tumor markers and manifested as dermatomyositis.
Breast Cancer, 1: 65-68, 1994
Tateyama H, Yang Y, Eimoto T, Tada T, Inagaki H, Nakamura T, Iwase H, Kobayashi S:
Proliferating cell nuclear antigen expression in follicular tumors of the thyroid with special reference to oxyphilic cell lesions.
Virchows Archiv 424: 533 537, 1994
1993
Iwase H, Kobayashi S, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Yamashita T, Naito A, Itoh K, Masaoka A:
Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.
Breast Cancer Res Treat 28: 215-221, 1993
Yamashita H, Kobayashi S, Iwase H, Itoh Y, Kuzushima T, Iwata H, Naito A, Yamashita T, Masaoka A, Kimura N:
Analysis of oncogenes and tumor suppressor genes in human breast cancer.
Jpn J Cancer Res 84: 871-878, 1993
-1992
Kobayashi S, Iwase H, Ito Y, Fukuoka H, Yamashita H, Kuzushima T, Iwata H, Masaoka A, Kimura N:
Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancer.
Jpn J Cancer Res 83: 859-865, 1992
Kobayashi S, Iwase H, Matsuo K, Fukuoka H, Ito Y, Masaoka A:
Primary adrenocortical tumors in autopsy records -A survey of "Cumulative reports in Japan" from 1973 to 1984.
Jpn J Surg 21: 494-498, 1991
Tanaka H, Kobayashi S, Masaoka A, Honda S, Yamaguchi K:
Hypercalcemia induced by parathyroid hormone-related protein from lung cancer tissue.
Chest 100: 1451-1453, 1991
Kobayashi S, Iwase H:
Prognostic factors and evaluation of effect in drug therapy of breast cancer, Cancer Chemotherapy; Challenges for the future.
Vol. 5, p.183 190, Excerpta Medica Ltd (Tokyo) 1990
Kobayashi S, Iwase H, Karamatsu S, Matsuo K, Masaoka A, Miyagawa T:
The clinical value of serum CA 15-3 assay postoperatively in breast cancer patients.
Jpn J Surg 19: 278-282, 1989
Kobayashi S, Tobioka N, Samoto T, Kobayashi M, Iwase H, Masaoka A, Nakamura T, Shibata H, Amoh H, Matsuyama M.:
Breast cancer with osteoclast-like multinucleated giant cells.
Acta Pathol Jpn 34:1475-84, 1984
Nagai R, Kataoka M, Kobayashi S, Ishihara K, Tobioka N, Nakashima K, Nruse M, Sauto K, Sakuma S:
Estrogen and progesterone receptors in human breast cancer with concomitant assay of plasma 17beta-estradiol, progesterone, and prolactin levels.
Cancer Res 39: 1834-1840, 1979
Nomura Y, Kobayashi S, Takatani O, Sugano H, Matsumoto K, McGuire WL:
Estrogen receptor and endocrine responsiveness in Japanese versus American breast cancer patients.
Cancer Res 37: 106-10, 1977
Kobayashi S:
Studies on the estrogen-receptors in human breast cancer.
Nagoya Med J 16: 165-76, 1971
和文論文、総説、著書
2008年
小林俊三、山下啓子、遠山竜也、杉浦博士、近藤直人：EBM (evidence based medicine) の陥穽 超若年乳癌患者．乳癌の臨床23:81-86, 2008
